Evidence map›Paper›PMID 37853157›Full record

ArticleNature protocols2023

Precise surface functionalization of PLGA particles for human T cell modulation.

Pierce Hadley, Yuanzhou Chen, Lariana Cline, Zhiyuan Han, Qizhi Tang, Xiao Huang, Tejal Desai

Open access · greenAbstract read
In one paragraph

Article in Nature protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pierce HadleyMedical Scientist Training Program, University of California, San Francisco, CA, USA.ORCID 0000-0002-6859-500X
Yuanzhou ChenDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
Lariana ClineDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
Zhiyuan HanDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
Qizhi TangDiabetes Center, University of California, San Francisco, CA, USA.ORCID 0000-0001-7313-3574
Xiao HuangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA. xh324@drexel.edu.ORCID 0000-0001-7733-9094
Tejal DesaiUC Berkeley-UCSF Graduate Program in Bioengineering, UCSF Mission Bay Campus, San Francisco, CA, USA. tejal_desai@brown.edu.ORCID 0000-0003-3409-9208
University of California, San Francisco · USGladstone Institutes · US

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
UCSF/UCB Joint Graduate Group in BIoengineeringT32GM008155 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A. · 1985 to 2020
$12.2M
Medical Scientist Training Program (T32 NRSA Training Grant)T32GM141323 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aimee Kao · 2021 to 2026
$10.5M
User-control and safetyU54CA244438 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2019 to 2022
$7.8M
NCI NIH HHS U54 CA244438NIDDK NIH HHS P30 DK063720NIGMS NIH HHS T32 GM008155NIGMS NIH HHS T32 GM141323
6 · The paper itself

Abstract

The biofunctionalization of synthetic materials has extensive utility for biomedical applications, but approaches to bioconjugation typically show insufficient efficiency and controllability. We recently developed an approach by building synthetic DNA scaffolds on biomaterial surfaces that enables the precise control of cargo density and ratio, thus improving the assembly and organization of functional cargos. We used this approach to show that the modulation and phenotypic adaptation of immune cells can be regulated using our precisely functionalized biomaterials. Here, we describe the three key procedures, including the fabrication of polymeric particles engrafted with short DNA scaffolds, the attachment of functional cargos with complementary DNA strands, and the surface assembly control and quantification. We also explain the critical checkpoints needed to ensure the overall quality and expected characteristics of the biological product. We provide additional experimental design considerations for modifying the approach by varying the material composition, size or cargo types. As an example, we cover the use of the protocol for human primary T cell activation and for the identification of parameters that affect ex vivo T cell manufacturing. The protocol requires users with diverse expertise ranging from synthetic materials to bioconjugation chemistry to immunology. The fabrication procedures and validation assays to design high-fidelity DNA-scaffolded biomaterials typically require 8 d.

Indexed as

Biocompatible MaterialsT-LymphocytesDNAHumansPolymersBiocompatible MaterialsDNAPolymers

Identifiers

PMID37853157
PMCPMC10775953
OpenAlexW4387739495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.